Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life

Debbie S. Gipson, Howard Trachtman, Frederick J. Kaskel, Milena K. Radeva, Jennifer Gassman, Tom H. Greene, Marva M. Moxey-Mims, Ronald J. Hogg, Sandra L. Watkins, Richard N. Fine, John P. Middleton, V. M. Vehaskari, Susan L. Hogan, Suzzane Vento, Patti A. Flynn, Leslie M. Powell, June L. McMahan, Norman Siegel, Aaron L. Friedman

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Optimal therapy of patients with steroid-resistant primary focal segmental glomerulosclerosis (FSGS) remains controversial. This report describes the initial study design, baseline characteristics, and quality of life of patients enrolled in the FSGS Clinical Trial, a large multicenter randomized study of this glomerulopathy comparing a 12-month regimen of cyclosporine to the combination of mycophenolate mofetil and oral dexamethasone. Patients with age ranging 2-40 years, with an estimated glomerular filtration rate >40 ml/min per 1.73 m 2, a first morning urine protein-to-creatinine ratio over one, and resistant to corticosteroids were eligible. The primary outcome was complete or partial remission of proteinuria over 52 weeks after randomization. In all, 192 patients were screened, of whom 138 were randomized for treatment. Ethnic distributions were 53 black, 78 white, and 7 other. By self- or parent-proxy reporting, 26 of the 138 patients were identified as Hispanic. The baseline glomerular filtration rate was 112.4 (76.5, 180.0) ml/min per 1.73 m 2, and urine protein was 4.0 (2.1, 5.3) g/g. Overall, the quality of life of the patients with FSGS was lower than healthy controls and similar to that of patients with end-stage renal disease. Thus, the impact of FSGS on quality of life is significant and this measurement should be included in all trials.

Original languageEnglish (US)
Pages (from-to)678-685
Number of pages8
JournalKidney International
Volume79
Issue number6
DOIs
StatePublished - Mar 2011

Fingerprint

Focal Segmental Glomerulosclerosis
Quality of Life
Clinical Trials
Glomerular Filtration Rate
Urine
Mycophenolic Acid
Proxy
Random Allocation
Proteinuria
Hispanic Americans
Dexamethasone
Cyclosporine
Multicenter Studies
Chronic Kidney Failure
Creatinine
Adrenal Cortex Hormones
Proteins
Steroids
Therapeutics

Keywords

  • focal segmental glomerulosclerosis
  • proteinuria
  • quality of life
  • randomized controlled trial

ASJC Scopus subject areas

  • Nephrology

Cite this

Gipson, D. S., Trachtman, H., Kaskel, F. J., Radeva, M. K., Gassman, J., Greene, T. H., ... Friedman, A. L. (2011). Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. Kidney International, 79(6), 678-685. https://doi.org/10.1038/ki.2010.485

Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. / Gipson, Debbie S.; Trachtman, Howard; Kaskel, Frederick J.; Radeva, Milena K.; Gassman, Jennifer; Greene, Tom H.; Moxey-Mims, Marva M.; Hogg, Ronald J.; Watkins, Sandra L.; Fine, Richard N.; Middleton, John P.; Vehaskari, V. M.; Hogan, Susan L.; Vento, Suzzane; Flynn, Patti A.; Powell, Leslie M.; McMahan, June L.; Siegel, Norman; Friedman, Aaron L.

In: Kidney International, Vol. 79, No. 6, 03.2011, p. 678-685.

Research output: Contribution to journalArticle

Gipson, DS, Trachtman, H, Kaskel, FJ, Radeva, MK, Gassman, J, Greene, TH, Moxey-Mims, MM, Hogg, RJ, Watkins, SL, Fine, RN, Middleton, JP, Vehaskari, VM, Hogan, SL, Vento, S, Flynn, PA, Powell, LM, McMahan, JL, Siegel, N & Friedman, AL 2011, 'Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life', Kidney International, vol. 79, no. 6, pp. 678-685. https://doi.org/10.1038/ki.2010.485
Gipson, Debbie S. ; Trachtman, Howard ; Kaskel, Frederick J. ; Radeva, Milena K. ; Gassman, Jennifer ; Greene, Tom H. ; Moxey-Mims, Marva M. ; Hogg, Ronald J. ; Watkins, Sandra L. ; Fine, Richard N. ; Middleton, John P. ; Vehaskari, V. M. ; Hogan, Susan L. ; Vento, Suzzane ; Flynn, Patti A. ; Powell, Leslie M. ; McMahan, June L. ; Siegel, Norman ; Friedman, Aaron L. / Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. In: Kidney International. 2011 ; Vol. 79, No. 6. pp. 678-685.
@article{c4fffbfc688744cfbe67c88659fc17e8,
title = "Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life",
abstract = "Optimal therapy of patients with steroid-resistant primary focal segmental glomerulosclerosis (FSGS) remains controversial. This report describes the initial study design, baseline characteristics, and quality of life of patients enrolled in the FSGS Clinical Trial, a large multicenter randomized study of this glomerulopathy comparing a 12-month regimen of cyclosporine to the combination of mycophenolate mofetil and oral dexamethasone. Patients with age ranging 2-40 years, with an estimated glomerular filtration rate >40 ml/min per 1.73 m 2, a first morning urine protein-to-creatinine ratio over one, and resistant to corticosteroids were eligible. The primary outcome was complete or partial remission of proteinuria over 52 weeks after randomization. In all, 192 patients were screened, of whom 138 were randomized for treatment. Ethnic distributions were 53 black, 78 white, and 7 other. By self- or parent-proxy reporting, 26 of the 138 patients were identified as Hispanic. The baseline glomerular filtration rate was 112.4 (76.5, 180.0) ml/min per 1.73 m 2, and urine protein was 4.0 (2.1, 5.3) g/g. Overall, the quality of life of the patients with FSGS was lower than healthy controls and similar to that of patients with end-stage renal disease. Thus, the impact of FSGS on quality of life is significant and this measurement should be included in all trials.",
keywords = "focal segmental glomerulosclerosis, proteinuria, quality of life, randomized controlled trial",
author = "Gipson, {Debbie S.} and Howard Trachtman and Kaskel, {Frederick J.} and Radeva, {Milena K.} and Jennifer Gassman and Greene, {Tom H.} and Moxey-Mims, {Marva M.} and Hogg, {Ronald J.} and Watkins, {Sandra L.} and Fine, {Richard N.} and Middleton, {John P.} and Vehaskari, {V. M.} and Hogan, {Susan L.} and Suzzane Vento and Flynn, {Patti A.} and Powell, {Leslie M.} and McMahan, {June L.} and Norman Siegel and Friedman, {Aaron L.}",
year = "2011",
month = "3",
doi = "10.1038/ki.2010.485",
language = "English (US)",
volume = "79",
pages = "678--685",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life

AU - Gipson, Debbie S.

AU - Trachtman, Howard

AU - Kaskel, Frederick J.

AU - Radeva, Milena K.

AU - Gassman, Jennifer

AU - Greene, Tom H.

AU - Moxey-Mims, Marva M.

AU - Hogg, Ronald J.

AU - Watkins, Sandra L.

AU - Fine, Richard N.

AU - Middleton, John P.

AU - Vehaskari, V. M.

AU - Hogan, Susan L.

AU - Vento, Suzzane

AU - Flynn, Patti A.

AU - Powell, Leslie M.

AU - McMahan, June L.

AU - Siegel, Norman

AU - Friedman, Aaron L.

PY - 2011/3

Y1 - 2011/3

N2 - Optimal therapy of patients with steroid-resistant primary focal segmental glomerulosclerosis (FSGS) remains controversial. This report describes the initial study design, baseline characteristics, and quality of life of patients enrolled in the FSGS Clinical Trial, a large multicenter randomized study of this glomerulopathy comparing a 12-month regimen of cyclosporine to the combination of mycophenolate mofetil and oral dexamethasone. Patients with age ranging 2-40 years, with an estimated glomerular filtration rate >40 ml/min per 1.73 m 2, a first morning urine protein-to-creatinine ratio over one, and resistant to corticosteroids were eligible. The primary outcome was complete or partial remission of proteinuria over 52 weeks after randomization. In all, 192 patients were screened, of whom 138 were randomized for treatment. Ethnic distributions were 53 black, 78 white, and 7 other. By self- or parent-proxy reporting, 26 of the 138 patients were identified as Hispanic. The baseline glomerular filtration rate was 112.4 (76.5, 180.0) ml/min per 1.73 m 2, and urine protein was 4.0 (2.1, 5.3) g/g. Overall, the quality of life of the patients with FSGS was lower than healthy controls and similar to that of patients with end-stage renal disease. Thus, the impact of FSGS on quality of life is significant and this measurement should be included in all trials.

AB - Optimal therapy of patients with steroid-resistant primary focal segmental glomerulosclerosis (FSGS) remains controversial. This report describes the initial study design, baseline characteristics, and quality of life of patients enrolled in the FSGS Clinical Trial, a large multicenter randomized study of this glomerulopathy comparing a 12-month regimen of cyclosporine to the combination of mycophenolate mofetil and oral dexamethasone. Patients with age ranging 2-40 years, with an estimated glomerular filtration rate >40 ml/min per 1.73 m 2, a first morning urine protein-to-creatinine ratio over one, and resistant to corticosteroids were eligible. The primary outcome was complete or partial remission of proteinuria over 52 weeks after randomization. In all, 192 patients were screened, of whom 138 were randomized for treatment. Ethnic distributions were 53 black, 78 white, and 7 other. By self- or parent-proxy reporting, 26 of the 138 patients were identified as Hispanic. The baseline glomerular filtration rate was 112.4 (76.5, 180.0) ml/min per 1.73 m 2, and urine protein was 4.0 (2.1, 5.3) g/g. Overall, the quality of life of the patients with FSGS was lower than healthy controls and similar to that of patients with end-stage renal disease. Thus, the impact of FSGS on quality of life is significant and this measurement should be included in all trials.

KW - focal segmental glomerulosclerosis

KW - proteinuria

KW - quality of life

KW - randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=79952186177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952186177&partnerID=8YFLogxK

U2 - 10.1038/ki.2010.485

DO - 10.1038/ki.2010.485

M3 - Article

C2 - 21178977

AN - SCOPUS:79952186177

VL - 79

SP - 678

EP - 685

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 6

ER -